Literature DB >> 26603640

suPAR: The unspecific marker for disease presence, severity and prognosis.

Jesper Eugen-Olsen1, Evangelos J Giamarellos-Bourboulis2.   

Abstract

Investigation of biomarkers that can promptly predict unfavourable outcome of critically illness is an emerging necessity taking into consideration the need for early intervention, the shortage of available beds in intensive care units and the considerable cost of hospitalisation. The most promising biomarker is soluble urokinase-type plasminogen activator receptor (suPAR). Three studies in large populations of critically ill patients and patients admitted to the emergency department have shown that concentrations >12 ng/mL can safely predict unfavourable outcome. This review presents a thorough analysis of the data from these studies.
Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Biomarker; Prognosis; suPAR

Mesh:

Substances:

Year:  2015        PMID: 26603640     DOI: 10.1016/j.ijantimicag.2015.10.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  15 in total

1.  Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.

Authors:  Nels C Olson; Laura M Raffield; Anne H Moxley; Tyne W Miller-Fleming; Paul L Auer; Nora Franceschini; Debby Ngo; Timothy A Thornton; Ethan M Lange; Yun Li; Deborah A Nickerson; Neil A Zakai; Robert E Gerszten; Nancy J Cox; Adolfo Correa; Karen L Mohlke; Alexander P Reiner
Journal:  Circ Genom Precis Med       Date:  2021-10-28

2.  Soluble Urokinase Receptor Levels in Secondary Focal Segmental Glomerulosclerosis.

Authors:  Pingping Sun; Lei Yu; Jing Huang; Suxia Wang; Wanzhong Zou; Li Yang; Gang Liu
Journal:  Kidney Dis (Basel)       Date:  2019-05-27

3.  Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.

Authors:  Rafael Fernandez-Botran; Irmgardt Alicia Wellmann; Clas Une; Ericka Méndez-Chacón; Elisa Hernández de Rodas; Bikash Bhandari; Carmen I Villagrán de Tercero
Journal:  Am J Trop Med Hyg       Date:  2020-04-16       Impact factor: 2.345

Review 4.  Organization, evolution and functions of the human and mouse Ly6/uPAR family genes.

Authors:  Chelsea L Loughner; Elspeth A Bruford; Monica S McAndrews; Emili E Delp; Sudha Swamynathan; Shivalingappa K Swamynathan
Journal:  Hum Genomics       Date:  2016-04-21       Impact factor: 4.639

5.  Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls.

Authors:  Peter Jirak; Rudin Pistulli; Michael Lichtenauer; Bernhard Wernly; Vera Paar; Lukas J Motloch; Richard Rezar; Christian Jung; Uta C Hoppe; P Christian Schulze; Daniel Kretzschmar; Rüdiger C Braun-Dullaeus; Tarek Bekfani
Journal:  J Clin Med       Date:  2020-04-15       Impact factor: 4.241

6.  Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients.

Authors:  Athanasios Chalkias; Angeliki Mouzarou; Evangelia Samara; Theodoros Xanthos; Eleni Ischaki; Ioannis Pantazopoulos
Journal:  Mol Diagn Ther       Date:  2020-10       Impact factor: 4.074

7.  Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.

Authors:  Hendrik Gussen; Philipp Hohlstein; Matthias Bartneck; Klaudia Theresa Warzecha; Lukas Buendgens; Tom Luedde; Christian Trautwein; Alexander Koch; Frank Tacke
Journal:  J Intensive Care       Date:  2019-04-27

8.  SuPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective, observational cohort study.

Authors:  Peter Polzik; Olav Grøndal; Juliette Tavenier; Martin B Madsen; Ove Andersen; Morten Hedetoft; Ole Hyldegaard
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

9.  Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group.

Authors:  George Dimopoulos; Nikoletta Rovina; Maria Patrani; Eleni Antoniadou; Dimitrios Konstantonis; Konstantina Vryza; Glykeria Vlachogianni; Miltiades Kyprianou; Christina Routsi; Evangelos J Giamarellos-Bourboulis
Journal:  BMC Infect Dis       Date:  2019-10-07       Impact factor: 3.090

10.  High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.

Authors:  Sven H Loosen; Frank Tacke; Niklas Püthe; Marcel Binneboesel; Georg Wiltberger; Patrick H Alizai; Jakob N Kather; Pia Paffenholz; Thomas Ritz; Alexander Koch; Frank Bergmann; Christian Trautwein; Thomas Longerich; Christoph Roderburg; Ulf P Neumann; Tom Luedde
Journal:  Carcinogenesis       Date:  2019-08-22       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.